Tech Company Financing Transactions
Prokarium Funding Round
Prokarium, operating out of London, England, received $30 million from private investors.
Transaction Overview
Company Name
Announced On
2/9/2023
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds for clinical development of its oncology candidate in non-muscle invasive bladder cancer and accelerate platform discovery.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
London Bioscience Innovation Centre, 2 Royal College St,
London, England, NW1 0NH
UK
London, England, NW1 0NH
UK
Phone
Undisclosed
Website
Email Address
Overview
Prokarium is leveraging the evolutionary advantages of a proprietary strain of Salmonella as a microbial immunotherapy platform. Naturally tumor targeting and oncolytic. Overcomes the suppressive tumor microenvironment. Targets multiple pathways to elicit strong anti-tumor immunity. Extensive opportunities to deliver diverse cargo.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kristen Albright
Chief Financial Officer
Julia Jones
Chief Marketing Officer
Josi Holz
Chief Scientific Officer
Livija Deban
Browse more venture capital transactions:
Prev: 2/9/2023: Vault Laboratories venture capital transaction
Next: 2/10/2023: Spectrum.Life venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs